WallStSmart

Park Ha Biological Technology Co., Ltd. (BYAH)vsKenvue Inc. (KVUE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kenvue Inc. generates 605572% more annual revenue ($15.29B vs $2.52M). KVUE leads profitability with a 10.6% profit margin vs 0.0%. KVUE earns a higher WallStSmart Score of 68/100 (B-).

BYAH

Avoid

30

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: -16.66

KVUE

Strong Buy

68

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 4.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BYAH.

KVUESignificantly Overvalued (-87.1%)

Margin of Safety

-87.1%

Fair Value

$9.91

Current Price

$17.71

$7.80 premium

UndervaluedFair: $9.91Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BYAH2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

KVUE2 strengths · Avg: 8.0/10
Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

EPS GrowthGrowth
46.9%8/10

Earnings expanding 46.9% YoY

Areas to Watch

BYAH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.77M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

KVUE2 concerns · Avg: 3.0/10
Revenue GrowthGrowth
4.5%4/10

4.5% revenue growth

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BYAH

The strongest argument for BYAH centers on Price/Book, Debt/Equity.

Bull Case : KVUE

The strongest argument for KVUE centers on Operating Margin, EPS Growth. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bear Case : BYAH

The primary concerns for BYAH are EPS Growth, Market Cap, Profit Margin.

Bear Case : KVUE

The primary concerns for KVUE are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

KVUE is growing revenue faster at 4.5% — sustainability is the question.

KVUE generates stronger free cash flow (350M), providing more financial flexibility.

Monitor HOUSEHOLD & PERSONAL PRODUCTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KVUE scores higher overall (68/100 vs 30/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Park Ha Biological Technology Co., Ltd.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · China

Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company is headquartered in Wuxi, the People's Republic of China.

Kenvue Inc.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kenvue Inc. is a consumer health company globally.

Visit Website →

Want to dig deeper into these stocks?